{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Number of treatment related AEs that occur or worsen after the first dose of study treatment","groups":[{"description":"ALT-801: Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle","id":"OG000","title":"ALT-801 0.04mg/kg"},{"description":"ALT-801: Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle","id":"OG001","title":"ALT-801 0.06mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"7 weeks","title":"Number of Participants With Treatment-Related Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}